Premium
Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan
Author(s) -
VERSCHRAEGEN C. F.,
LEVENBACK C.,
VINCENT M.,
WOLF J.,
BEVERS M.,
LOYER E.,
KUDELKA A. P.,
KAVANAGH J. J.
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb07062.x
Subject(s) - medicine , gynecologic oncology , topotecan , taxane , ovarian cancer , gynecologic cancer , oncology , cancer , gynecology , breast cancer , chemotherapy